Personalized cancer vaccines (PCVs) have changed the way we think about treating cancer. Instead of developing therapies for broad patient populations, these approaches are designed around the unique molecular profile of an individual patient's tumor. It’s one of the clearest examples that medicine is heading away from standardized treatment models and toward personalized therapies.
The science behind these therapies has progressed rapidly over the last decade, driven by advances in genomics, bioinformatics, and mRNA-based platforms. Most recently, Merck and Moderna reported the first positive phase III readout for a personalized mRNA cancer vaccine, with intismeran autogene plus pembrolizumab improving recurrence-free and distant-metastasis-free survival in patients with resected melanoma.
Yet the industry is increasingly confronted by a different challenge: how to manufacture these therapies quickly and reliably enough to reach patients within the narrow window when treatment can make the greatest difference.
Manufacturing: a race against time
As more PCV programs move toward commercialization, attention is shifting from scientific feasibility to operational execution. A key constraint is that much of today’s manufacturing infrastructure still relies on plasmid DNA (pDNA), which is produced via bacterial fermentation in large bioreactors, requiring multiple upstream and downstream processing steps spanning weeks or even months.
While this approach is effective for traditional therapies manufactured at scale, these long development timelines become risky when each patient's treatment must be tailored to their specific neoantigens.
Unlike traditional therapies that can be produced and stored in advance, these treatments are manufactured in response to a patient's tumor biopsy. With many programs targeting a six-to-nine-week turnaround from sequencing to dosing, manufacturing speed directly impacts whether a therapy can reach a patient in time.
As a result, the industry is exploring alternative approaches to DNA manufacturing that are better suited for personalized medicine. Synthetic DNA, produced through cell-free manufacturing processes, eliminates the need for bacterial fermentation, shrinking development timelines. With both the ability to shorten production and improve manufacturing flexibility, synthetic DNA can better position PCVs for broader adoption.
Beyond speed: purity, consistency, and safety
In PCVs, manufacturers must deliver the purity, consistency, and safety required for clinical use. Again, this is where the quality of DNA starting materials comes in, and it’s another area where synthetic DNA shines.
Legacy pDNA manufacturing relies on complex biological processes and includes bacterial backbone sequences that can create downstream issues with purification, characterization, and product release. In personalized medicine, the reproducibility of the starting material can directly impact the efficiency and reliability of the overall manufacturing process, leaving little room for variability.
Synthetic, cell-free DNA takes some of that variability out of the equation. Removing bacterial components reduces endotoxins, antibiotic resistance genes, and other contaminants that can complicate purification and product release. For a one-patient therapy, that level of control is incredibly important. Cleaner DNA starting material can mean a more consistent process, fewer downstream hurdles, and increased patient safety.
Building tools and processes fit for the future
PCVs are one of the most promising advances in oncology, but their long-term success will depend on more than scientific innovation alone. The next phase of progress will depend on whether the industry is willing to modernize the systems that sit beneath the science.
The focus should be on building manufacturing infrastructure designed for individual therapies by rethinking how DNA is produced, how manufacturing workflows are structured, and how quality is maintained in these personalized environments.
The science has shown what is possible; now manufacturing has to make it practical.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
